Evidence map›Paper›PMID 40893810›Full record

Observational studyJournal of medicine and life2025

Real-world characteristics of systemic mastocytosis in Romania: insights from a reference-center-based descriptive study.

Delia Soare, Dan Soare, Brîndușa Petruțescu, Oana Firescu, Poliana Leru, Corina Silvia Pop, Lucian Negreanu, Vlad Voiculescu, Horia Bumbea

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of medicine and life, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Delia SoareBone Marrow Transplantation Unit, University Emergency Hospital Bucharest, Bucharest, Romania.
Dan SoareBone Marrow Transplantation Unit, University Emergency Hospital Bucharest, Bucharest, Romania.
Brîndușa PetruțescuAllergology, University Emergency Hospital Bucharest, Bucharest, Romania.
Oana FirescuDermatology, University Emergency Hospital Bucharest, Bucharest, Romania.
Poliana LeruAllergology Department, Colentina Clinical Hospital, Bucharest, Romania.
Corina Silvia PopGastroenterology II, University Emergency Hospital Bucharest, Bucharest, Romania.
Lucian NegreanuGastroenterology I, University Emergency Hospital Bucharest, Bucharest, Romania.
Vlad VoiculescuOncological Dermatology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Horia BumbeaDepartment of Dermatology and Allergology, Elias Emergency University Hospital, Bucharest, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic mastocytosis (SM) is a rare clonal mast cell disease characterized by heterogeneous clinical presentations and molecular features that vary across different regions; however, data from Central-Eastern Europe remain limited. This study aimed to describe the demographic, clinical, laboratory, and molecular characteristics of Romanian adults diagnosed with SM and followed at the national reference center for mast cell disorders in Bucharest, while also exploring real-world management patterns and outcomes. We conducted a retrospective observational study including 162 adult patients evaluated between January 2006 and March 2025 who met the 2022 World Health Organization criteria for SM. Data extracted from electronic medical records included WHO subtype,

Indexed as

Mastocytosis, SystemicAdultAgedCD2 AntigensFemaleHumansInterleukin-2 Receptor alpha SubunitMaleMiddle AgedMutationProto-Oncogene Proteins c-kitRetrospective StudiesRomaniaTryptasesCD2 AntigensInterleukin-2 Receptor alpha SubunitProto-Oncogene Proteins c-kitTryptasesASM, Aggressive Systemic Mastocytosisclinical phenotypeCM, Cutaneous MastocytosisepidemiologyFLT3, FMS-like Tyrosine Kinase 3ISM, Indolent Systemic MastocytosisIWG-MRT-ECNM, International Working Group – Myeloproliferative Neoplasms Research & Treatment – European Competence Network on MastocytosisKIT D816V mutationKIT proto-oncogene, receptor tyrosine kinaseMCL, Mast Cell LeukemiaMRI, Magnetic Resonance ImagingRomaniaSM-AHN, Systemic Mastocytosis with Associated Hematologic NeoplasmSM-ana, Systemic Mastocytosis without skin involvement associated with recurrent anaphylaxis or vascular collapseSM, Systemic MastocytosisSSM, Smoldering Systemic Mastocytosissystemic mastocytosistargeted therapyTKIs, Tyrosine Kinase InhibitorsWDSM, Well-Differentiated Systemic MastocytosisWHO, World Health Organization

Identifiers

PMID40893810
PMCPMC12393665

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.